Tarsons Products Limited TARSONS NSEPHARMA

Healthcare · Medical Instruments & Supplies · India

https://www.tarsons.com

Tarsons Products Limited manufactures and trades in scientific plastic labware products in India and internationally. The company offers bottles and carboys; boxes and racks; cell cell culture ware, centrifuge ware, clamps and stands, cryoware, desiccator, tubings and connectors, filtration, genomics and PCR consumables, laboratory equipment and utilities, liquid handling consumables and reusables, magnetic stirrer bar, pp storage plates, sampling aids, vials and tubes, and volumetric reusables. It also provides general lab ware products. Its products are used in molecular biology, cell culture, genomics, proteomics, and immunology. Tarsons Products Limited was incorporated in 1983 and is headquartered in Kolkata, India.

Market & Price

Market Cap

₹1,114.46 Cr

Current Price

₹209.46

High / Low (52W)

₹395.70 / ₹166.46

Beta

Valuation

Stock P/E

78.16

Industry PE

37.60

Forward P/E

16.11

PEG Ratio

Book Value

₹116.95

Price to Book

1.79

P/S

2.49

EV/EBITDA

10.39

Dividend Yield

Profitability & Returns

ROCE

4.82%

ROE

2.27%

ROA

2.51%

Profit Margin

3.21%

Op Margin

9.25%

EPS (Latest Qtr)

₹0.79

EPS (TTM)

₹2.68

Balance Sheet & Liquidity

Debt/Equity

0.62

Quick Ratio

0.43

Current Ratio

1.01

Debt

₹392.96 Cr

Total Assets

₹1,185.82 Cr

Current Assets

₹265.75 Cr

Working Capital

₹1.56 Cr

Ownership

Promoter Holding

73.87%

Chg in Prom Hold

FII / Inst Holding

2.08%

Chg in FII Hold

Financial Snapshot

Enterprise Value

₹1,476.25 Cr

Total Revenue (TTM)

₹446.68 Cr

EBITDA

₹142.10 Cr

Free Cash Flow

₹65.42 L

Operating Cash Flow

₹118.48 Cr

Shares Outstanding

₹5.32 Cr

Gross Margin

68.91%

Payout Ratio

0.00%

Growth (CAGR)

Revenue 5Y

14.51%

Profit 5Y

-43.81%

Revenue (YoY)

13.20%

Earnings (YoY)

-58.90%

PROS

Compounding revenue at 14.5% over 5 years.
Generates positive free cash flow.

CONS

Trading at a high P/E of 78.2.
Earnings shrank at -43.8% CAGR over 5 years.
Trading 47.1% below its 52-week high.
In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Price Chart

NSE TradingView Screener.in

Fundamental Growth

Period: Metric:

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP ₹	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	TARSONS Tarsons Products Limited NSEPHARMA	209.46	78.16	₹1,114.46 Cr	-	4.82%	2.27%	14.51%	-43.81%
2	SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA	1,799.20	37.59	₹4.32 L Cr	0.92%	17.94%	14.72%	10.39%	10.65%
3	DIVISLAB Divi's Laboratories Limited NSEPHARMA	6,667.00	68.97	₹1.77 L Cr	0.45%	18.96%	16.19%	11.27%	12.08%
4	TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA	4,410.80	68.96	₹1.49 L Cr	0.86%	9.06%	16.98%	13.27%	20.21%
5	CIPLA Cipla Limited NIFTY50NSEAIPHARMA	1,401.00	29.16	₹1.13 L Cr	0.93%	14.88%	11.74%	7.23%	11.45%
6	DRREDDY Dr. Reddy's Laboratories Limited NIFTY50NSEAIPHARMA	1,303.50	25.90	₹1.09 L Cr	0.61%	14.00%	11.83%	10.96%	-2.35%
7	ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA	1,077.70	21.51	₹1.08 L Cr	0.09%	19.24%	18.32%	16.55%	36.99%
8	LUPIN Lupin Limited NIFTY_MIDNSEPHARMA	2,267.70	19.49	₹1.04 L Cr	0.53%	28.42%	26.91%	19.10%	131.46%
9	MANKIND Mankind Pharma Limited NIFTY_MIDNSEPHARMA	2,375.60	51.29	₹98,090.71 Cr	0.08%	13.78%	12.45%	17.73%	14.28%

Quarterly Results

Figures in INR.

Metric	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Revenue	-	-	112.69 Cr	91.36 Cr	102.33 Cr	107.89 Cr	120.93 Cr
Cost of Revenue	-	-	37.89 Cr	29.30 Cr	33.24 Cr	35.15 Cr	41.18 Cr
Gross Profit	-	-	74.80 Cr	62.06 Cr	69.09 Cr	72.75 Cr	79.75 Cr
Operating Expenses	-	-	57.80 Cr	57.29 Cr	64.13 Cr	66.27 Cr	74.56 Cr
Operating Income	-	-	17.00 Cr	4.77 Cr	4.96 Cr	6.48 Cr	5.19 Cr
EBITDA	-	-	40.80 Cr	28.04 Cr	33.25 Cr	38.59 Cr	41.10 Cr
Interest Expense	-	-	5.20 Cr	5.07 Cr	5.17 Cr	6.05 Cr	6.25 Cr
Pretax Income	-	-	15.57 Cr	3.03 Cr	5.59 Cr	7.51 Cr	5.77 Cr
Tax Provision	-	-	5.37 Cr	1.25 Cr	2.27 Cr	2.47 Cr	1.59 Cr
Net Income	-	-	10.20 Cr	1.78 Cr	3.32 Cr	5.04 Cr	4.18 Cr
Diluted EPS	1.93	-	1.92	0.34	0.62	0.95	0.79

Profit & Loss (Annual)

Figures in INR.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Revenue	-	281.36 Cr	294.74 Cr	392.41 Cr	422.51 Cr
Cost of Revenue	-	78.24 Cr	94.29 Cr	129.44 Cr	138.87 Cr
Gross Profit	-	203.12 Cr	200.45 Cr	262.97 Cr	283.64 Cr
Operating Expenses	-	98.63 Cr	137.25 Cr	214.74 Cr	262.24 Cr
Operating Income	-	104.49 Cr	63.20 Cr	48.23 Cr	21.40 Cr
EBITDA	-	141.62 Cr	111.19 Cr	126.69 Cr	140.97 Cr
Interest Expense	-	4.39 Cr	10.02 Cr	19.39 Cr	22.55 Cr
Pretax Income	-	108.72 Cr	60.77 Cr	44.80 Cr	21.90 Cr
Tax Provision	-	28.01 Cr	18.13 Cr	15.03 Cr	7.58 Cr
Net Income	-	80.71 Cr	42.64 Cr	29.77 Cr	14.32 Cr
Diluted EPS	19.46	15.17	8.01	5.60	-

Compounded Sales Growth

5 Years:	14.51%
1 Year:	13.20%

Compounded Profit Growth

5 Years:	-43.81%
1 Year:	-58.90%

Stock Price Performance

1 Year:	-45.51%
6 Months:	-7.99%
3 Months:	+12.92%
1 Month:	-4.76%

Balance Sheet (Annual)

Figures in INR.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Total Assets	-	725.68 Cr	972.18 Cr	1,080.04 Cr	1,185.82 Cr
Current Assets	-	252.03 Cr	235.28 Cr	242.58 Cr	265.75 Cr
Cash & Equivalents	-	59.06 Cr	17.11 Cr	25.13 Cr	23.19 Cr
Inventory	-	114.37 Cr	128.73 Cr	126.05 Cr	129.78 Cr
Receivables	-	65.80 Cr	77.89 Cr	79.62 Cr	85.39 Cr
Total Liabilities	-	156.38 Cr	359.32 Cr	449.83 Cr	551.23 Cr
Current Liabilities	-	62.91 Cr	213.16 Cr	175.73 Cr	264.19 Cr
Long Term Debt	-	80.69 Cr	102.01 Cr	204.87 Cr	209.53 Cr
Total Debt	-	110.69 Cr	269.02 Cr	339.17 Cr	392.96 Cr
Total Equity	-	569.30 Cr	612.86 Cr	630.21 Cr	634.69 Cr
Shares Outstanding	-	5.32 Cr	5.32 Cr	5.32 Cr	5.32 Cr

Cash Flows (Annual)

Figures in INR.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Operating Cash Flow	-	75.60 Cr	102.70 Cr	114.24 Cr	118.48 Cr
Investing Cash Flow	-	-178.55 Cr	-284.96 Cr	-145.49 Cr	-130.37 Cr
Financing Cash Flow	-	84.56 Cr	135.62 Cr	38.95 Cr	8.93 Cr
Capital Expenditure	-	-189.97 Cr	-184.33 Cr	-151.71 Cr	-125.58 Cr
Free Cash Flow	-	-114.37 Cr	-81.63 Cr	-37.47 Cr	-7.10 Cr
Net Change in Cash	-	-18.39 Cr	-46.63 Cr	7.70 Cr	-2.96 Cr

Ratios (Annual)

Figures in %.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Gross Margin %	-	72.2%	68.0%	67.0%	67.1%
Operating Margin %	-	37.1%	21.4%	12.3%	5.1%
Net Margin %	-	28.7%	14.5%	7.6%	3.4%
ROE %	-	14.2%	7.0%	4.7%	2.3%
ROCE %	-	15.8%	8.3%	5.3%	2.3%

Shareholding Pattern

Insiders

73.87%

Institutions

2.08%

Public Float

7.94%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for TARSONS

No recent headlines available.

TARSONS · Healthcare